JAK1 and JAK2 activation in healthy versus inflamed gums
Unraveling the Role of JAK1 and JAK2 Pathway in Periodontitis: Drivers of Immunopathology and Possible Therapeutic Targets
We will test whether the JAK1 and JAK2 immune-signaling pathways are more active in adults with periodontitis than in adults with healthy gums.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Chile Academic / other |
| Drugs / interventions | Chemotherapy, radiation |
| Locations | 1 site (Santiago, Metropolitan Region) |
| Trial ID | NCT07536204 on ClinicalTrials.gov |
What this trial studies
This observational study collects gingival biopsy samples from adults with healthy gums and from adults with periodontitis at a single clinic visit. Tissue samples will be analyzed for JAK1 and JAK2 pathway activation and mapped to histological compartments such as epithelium and lamina propria and to specific cell subpopulations. All participants will receive diagnosis and standard dental treatment for their gingival condition. No experimental drug or device is administered.
Who should consider this trial
Good fit: Adults who are systemically healthy and able to undergo a single gingival biopsy visit, including those with clinically healthy gingiva or with periodontitis, who are not pregnant and do not have recent immunosuppressive or antibiotic exposure, are ideal candidates.
Not a fit: People with active malignancy, recent chemotherapy or head/neck radiation, chronic viral infections (HBV/HCV/HIV), autoimmune disease, diabetes, recent immunosuppressive or cytokine therapy, heavy smoking (>10 cigarettes/day), pregnancy or lactation are excluded and unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the findings could point to JAK1/2 as a target for new treatments that reduce gum inflammation and attachment loss.
How similar studies have performed: JAK pathway activation and JAK inhibitor benefit have been demonstrated in other inflammatory diseases, but applying detailed gingival biopsy profiling to link JAK1/2 specifically to periodontitis is a relatively novel, mechanistic approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults * Sistemically healthy Exclusion Criteria: * Active Maliganancy * History of radiation to the head-neck region * Chemotherapy or radiation within the last 5 years * History of hepatitis B/C or HIV infection * Autoimmune diseases * Diagnosis of diabetes * Pregnancy or lactation * More than 3 hospitalizations over the last 3 years * Use of systemic antibiotics over the last 3 months * Use of systemic corticosteroids or immunosuppressants over the last 3 months * Use of cytokine therapy over the last 3 months * Use of large doses of pre/probiotic supplements over the last 3 months * Smoke more than 10 cigarettes per day
Where this trial is running
Santiago, Metropolitan Region
- Faculty of Dentistry, University of Chile — Santiago, Metropolitan Region, Chile (Recruiting)
Study contacts
- Study coordinator: Nicolas Dutzan, DDS, PhD
- Email: ndutzan@uchile.cl
- Phone: +56934037995
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.